Feature | Heart Valve Technology | January 15, 2016| Dave Fornell

FDA OKs TAVR Trial for Low-Risk Patients Using Sapien 3 Device

The trial will be the first to examine transcatheter valve use in low-risk patients, which may change the standard of care

Sapien III, Sapien 3, PARTNER III

The Edwards Sapien 3 valve uses a skirt at its base to prevent paravalvular leak. This is the newest version of the Sapien and will be used in the upcoming PARTNER III Trial.

Corevalve evolute R

A view of the first stage of deployment of the self-expanding Medtronic Corevalve Evolut R TAVR valve. 

January 15, 2016 — The U.S. Food and Drug Administration (FDA) has given its approval for an expanded indication study of Edwards' Sapien 3 valve in low-risk patients. This will be the first U.S. study of a transcatheter aortic valve replacement (TAVR) device in this patient population, which would normally receive an open-heart surgical valve replacement. If TAVR proves to be at least equal in outcomes to surgery, it will likely cause a paradigm shift in the standard of care.

Patients enrolled in the new PARTNER III Trial will be randomized to receive either the Sapien 3 TAVR or surgical aortic valve replacement (SAVR). The investigational device exemption (IDE) study will enroll elderly patients with severe, symptomatic aortic stenosis (AS) who have been determined by a heart team to be at low risk for mortality if they were to undergo SAVR.

To be eligible for the trial, patients must be at least 65 years old, exhibit symptoms of severe AS and be determined by a heart team to have a surgical risk score of less than 4 percent per the Society of Thoracic Surgeons (STS) adult cardiac surgery risk calculator. The trial is a non-inferiority study with a one-year composite endpoint that includes death, stroke and rehospitalization. Enrollment of approximately 1,300 patients at up to 50 sites is expected to begin during the second quarter of 2016. The trial also includes a 400-patient sub-study using advanced imaging to evaluate leaflet motion in tissue heart valves.

Changing the Standard of Care 
For decades, SAVR has been the standard treatment for severe aortic stenosis, but TAVR has rapidly replaced SAVR in high-risk patients the past few years due to excellent clinical trial results showing equal or better patient outcomes compared to SAVR. Today, TAVR is the first-line therapy for inoperable patients with severe AS and an alternative to SAVR in operable high-risk patients. 

Watch a video interview with Michael Reardon, M.D., about TAVR having better outcomes than SAVR in the CoreValve pivotal trial. Reardon was the chairman of the patient screening committee for the CoreValve U.S. pivotal trial.

With the value of TAVR proven in extreme- and high-risk patients, the focus of ongoing trials is to gain additional FDA indications in less-sick, intermediate-risk patients. The SURTAVI Trial is examining the use of the CoreValve versus SAVR, and the PARTNER IIA Trial using the Sapien versus SAVR in intermediate-risk patients. Both trials are recruiting patients and are widely expected to show positive results for TAVR. 

Evidence from one recent study in Europe suggests TAVR has comparable outcomes in intermediate patients. Between November 2006 and January 2010, 3,666 consecutive patients underwent either TAVI (n = 782) or SAVR (n = 2,884), and researchers matched patients with STS scores for intermediate-risk patients between the two groups. They found cumulative all-cause mortality at 30 days and one year was similar among propensity score-matched TAVI and SAVR patients at intermediate surgical risk.[1]

Newer Valves
There were some issues with the first-generation TAVR devices, including larger sizes requiring alternative access to the preferred femoral artery and vascular complications. To justify treating younger, healthier patients who do very well with SAVR, TAVR needs to show it can lower complication rates to be equal to SAVR in this population. 

However, second-generation TAVR devices approved by the FDA in 2015 address many of those limitations. The current-generation TAVR systems are the balloon-expandable Edwards Sapien 3, and the recapturable, self-expanding Medtronic CoreValve Evolut R System. Both systems have been revised to reduce paravalvular leak and make them easier to deliver, including a smaller vascular entry diameter, making them more compatible with femoral access. These newer devices are still limited to the treatment of extreme and high-risk patients suffering from severe, symptomatic AS.       

Watch a video interview with Juan Granada, M.D., on the development of new TAVR technology to address performance issues. Granada is the executive director and chief scientific officer of the Cardiovascular Research Foundation's Skirball Center for Innovation.

1. Piazza N, Kalesan B, van Mieghem N, et al. “A 3-center comparison of 1-year mortality outcomes between transcatheter aortic valve implantation and surgical aortic valve replacement on the basis of propensity score matching among intermediate-risk surgical patients.” JACC Cardiovasc Interv. 2013 May;6(5):443-51. doi: 10.1016/j.jcin.2013.01.136.

2. Haussig S, Linke A. “Patient selection for TAVI 2015 - TAVI in low-risk patients: fact or fiction?” EuroIntervention. 2015 Sep;11 Suppl W:W86-91. doi: 10.4244/EIJV11SWA27.

Related Content

Novel Index Accurately Predicts PCI Success Post-Procedure Compared to Established Measurement Metrics
News | Cath Lab | June 19, 2019
Results from a comprehensive analysis demonstrate the effectiveness of measuring a non-hyperemic pressure ratio (NHPR...
Philips Healthcare, Volcano IVUS showing an implanted stent. IVUS might offer an alternative to contrast angiography in patients with acute kidney disease (AKD).
News | Cath Lab | June 14, 2019
June 14, 2019 – A late-breaking study examined the effects of intravascular ultrasound (IVUS) guided drug-eluting ste
Videos | Cath Lab | May 20, 2019
This is a walk through of the primary structural heart hybrid cath lab at...
Mobility May Predict Elderly Heart Attack Survivors' Repeat Hospital Stays
News | Cath Lab | April 23, 2019
Determining which elderly heart attack patients take longer to stand from a seated position and walk across a room may...
FDA Releases New Guidance on Medical Devices Containing Nitinol
News | Cath Lab | April 18, 2019
April 18, 2019 — The U.S.
Angiography shows a stenotic lesion in the mid right coronary artery, undilatable by standard high-pressure balloon angioplasty (inset, arrowheads). (B) Optical coherence tomography (OCT) cross-sectional (top) and longitudinal (bottom) images acquired before IVL and coregistered to the OCT lens (arrow in A) demonstrate severe near-circumferential calcification in the area of the stenosis. (C) Angiography demonstrates improvement in the area of stenosis after IVL lithoplasty.

Figure 2: Angiography demonstrates a stenotic lesion in the mid right coronary artery, undilatable by standard high-pressure balloon angioplasty (inset, arrowheads). (B) Optical coherence tomography (OCT) cross-sectional (top) and longitudinal (bottom) images acquired before IVL and coregistered to the OCT lens (arrow in A) demonstrate severe near-circumferential calcification (double-headed arrow) in the area of the stenosis. (C) Angiography demonstrates improvement in the area of stenosis after IVL (inset; note the cavitation bubbles generated by IVL [black arrows]). (D) OCT cross-sectional (top) and longitudinal (bottom) images acquired post-IVL and coregistered to the OCT lens (white arrow in C) demonstrate multiple calcium fractures and large acute luminal gain. (E) Angiography demonstrates complete stent expansion with the semicompliant stent balloon (inset) without the need for high-pressure noncompliant balloon inflation. (F) OCT cross-sectional (top) and longitudinal (bottom) images acquired post-stenting and coregistered to the OCT lens (arrow in E) demonstrate further fracture displacement (arrow), with additional increase in the acute area gain (5.17 mm2), resulting in full stent expansion and minimal malapposition.

Feature | Cath Lab | April 15, 2019 | Dean Kereiakes, M.D., FACC, FSCAI, and Jonathan Hill, M.D., DISRUPT CAD III Co-Principal Investigators
Over the last 40 years, despite multiple advancements in percutaneous coronary interventions, calcified lesions remai
BIOTRONIK’s PK Papyrus covered coronary stent. The stent ius used in emergency coronary artery dissections to repair the vessel wall.
Technology | Cath Lab | April 15, 2019
April 15, 2019 — Biotronik began its U.S.
Providing Follow-Up Care After Heart Attack Helps Reduce Readmissions, Deaths
News | Cath Lab | April 09, 2019
A program designed to help heart attack patients with the transition from hospital to outpatient care can reduce...
TherOx Receives FDA Approval for SuperSaturated Oxygen Therapy
Technology | Cath Lab | April 08, 2019
TherOx Inc. announced that the U.S. Food and Drug Administration (FDA) granted premarket approval for its...
Overlay Init